Study Population: Participants of the previous PRIMVAC vaccine trial and women aged 18 to 35 years Sample Size: 90 Study duration: 21 months Subject duration: 12 months if pregnancy doesn't occurred. In case of pregnancy, the participant will be followed up until the delivery. Study Design: Long term observational study comparing the immunology trend of 3 groups of i) women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso; ii) women of the same age and nulligravid who did not participate in the phase 1b trial iii) women of the same age and primigravid who did not participate in the phase 1b trial Co Primary objectives * To assess the dynamics of humoral immune response to the vaccine antigen during long term follow up of the study participants * To evaluate the functional durability of the humoral immune responses of women who participated in the phase 1b vaccine trial compared to women of the same age Secondary objectives * To assess the cellular immune response during the follow-up period * To assess the incidence of clinical malaria on study participants * To assess the prevalence of Placental Malaria in study participants and adverse outcomes such as maternal anemia, low birth weight, stillbirth and prematurity.
It is a long-term observational study comparing the immunology trend of 3 groups of women: * Women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso * Women of the same age and nulligravid who did not participate in the phase 1b trial * Women of the same age and primigravid who did not participate in the phase 1b trial The proposed cohort study will build on the previous phase 1b study which was conducted within the health district of Saponé (ClinicalTrials.gov Identifier: NCT02658253). The enrolment and follow up of the subjects will last 12 months. Pregnancy which occurred during the follow up period will monitored until the delivery. An additional six months is necessary for sample analysis in the laboratory, the data analysis and the preparation of reports and publications.
Study Type
OBSERVATIONAL
Enrollment
90
Groupe de Recherche Action en Santé
Ouagadougou, Burkina Faso
Geometric mean titer of antibodies
Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)
Time frame: month 0
Geometric mean titer of antibodies
Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)
Time frame: month 6
Geometric mean titer of antibodies
Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)
Time frame: month 12
Cross-reactivity against different VAR2CSA variants expressed on the surface of erythrocytes parasitized by various strains of Plasmodium falciparum by flow cytometry
VAR2CSA variants
Time frame: month 0
Percentage of binding inhibitory activity using various VAR2CSA expressing strains by CSA-binding inhibition assay (BIA) at different timepoints during the twelve months of follow up.
binding inhibitory activity
Time frame: month 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.